

526 Rec'd PCT/PTO 04 APR 2000

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

230-148P

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/509945  
NEW

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/JP99/04167	August 3, 1999	August 4, 1998

**TITLE OF INVENTION**

MUTANT BARNASE GENE AND TRANSGENIC PLANT TRANSFORMED BY SAID GENE

**APPLICANT(S) FOR DO/EO/US**

HAMADA, Kazuyuki; NAKAKIDO, Fumio

**Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:**

1.  This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2.  This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3.  This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39 (1).
4.  A proper Demand for International Preliminary Examination was made by the 19<sup>th</sup> month from the earliest claimed priority date
5.  A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a.  is transmitted herewith (required only if not transmitted by the International Bureau).
  - b.  has been transmitted by the International Bureau.
  - c.  is not required, as the application was filed in the United States Receiving Office (RO/US).
6.  A translation of the International Application into English (35 U.S.C. 371(c)(3)).
7.  Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(2)).
  - a.  are transmitted herewith (required only if not transmitted by the International Bureau).
  - b.  have been transmitted by the International Bureau.
  - c.  have not been made; however, the time limit for making such amendments has NOT expired.
  - d.  have not been made and will not be made.
8.  A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9.  An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10.  A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

**Items 11. to 16. below concern document(s) or information included:**

1.  An Information Disclosure Statement under 37 CFR 1.97 and 1.98.-1449 and International Search Report (PCT/ISA/210)
2.  An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
3.  A **FIRST** preliminary amendment.  
 A **SECOND** or **SUBSEQUENT** preliminary amendment.
4.  A substitute specification.
5.  A change of power of attorney and/or address letter.
6.  Other items or information:
  - 1.) PCT Request (PCT/RO/101)
  - 2.) Sequence Listing (12 pages)
  - 3.) Verification of Translation
  - 4.) Zero (0) sheets of Formal Drawings

JUN 7 45

DEPARTMENT OF COMMERCE

ATTORNEY'S DOCKET NUMBER

PCT/JP99/04167

230-148P

CALCULATIONS PTO USE ONLY

The following fees are submitted:

**PCT NATIONAL FEE (37 CFR 1.492(a)(1)-(5):**

either international preliminary examination fee (37 CFR 1.482)  
 nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO  
 and International Search Report not prepared by the EPO or JPO. .... \$970.00

International preliminary examination fee (37 CFR 1.482) not paid to  
 USPTO but International Search Report prepared by the EPO or JPO. .... \$840.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO  
 but international search fee (37 CFR 1.445(a)(2)) paid to USPTO. .... \$690.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO  
 but all claims did not satisfy provisions of PCT Article 33(1)-(4). .... \$670.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO  
 and all claims satisfied provisions of PCT Article 33(1)-(4). .... \$96.00

**ENTER APPROPRIATE BASIC FEE AMOUNT =**

Surcharge of \$130.00 for furnishing the oath or declaration later than  20  30 months from the earliest claimed priority date (37 CFR 1.492(e)).

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total Claims	30 - 20 =	10	X \$18.00
Independent Claims	5 - 3 =	2	X \$78.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)	Yes		+ \$260.00

**TOTAL OF ABOVE CALCULATIONS = \$ 1436.00**

Reduction of  $\frac{1}{2}$  for filing by small entity, if applicable. Verified Small Entity statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).

**SUBTOTAL = \$ 1436.00**

Processing fee of \$130.00 for furnishing the English translation later than  20  30 months from the earliest claimed priority date (37 CFR 1.492(f)). + \$ 0

**TOTAL NATIONAL FEE = \$ 1436.00**

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + \$ 40.00

**TOTAL FEES ENCLOSED = \$ 1476.00**

	Amount to be: refunded	\$
	charged	\$

a.  A check in the amount of \$ 1476.00 to cover the above fees is enclosed.

b.  Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the above fees.  
 A duplicate copy of this sheet is enclosed.

c.  The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-2448.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

Send all correspondence to:

Birch, Stewart, Kolasch &amp; Birch, LLP or Customer No. 2292

P.O. Box 747

Falls Church, VA 22040-0747

(703)205-8000

SIGNATURE

for

MURPHY, GERALD M., JR.

NAME

#28,977 (GMM)  
REGISTRATION NUMBER

qc

09/509945

527 Rec'd PCT/PTO 04 APR 2000

PATENT  
230-148P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: HAMADA, Kazuyuki et al.

Int'l. Appl. No.: PCT/JP99/04167

Appl. No.: New Group:

Filed: April 4, 2000 Examiner:

For: MUTANT BARNASE GENE AND TRANSGENIC  
PLANT TRANSFORMED BY SAID GENE

PRELIMINARY AMENDMENT

**BOX PATENT APPLICATION**

Assistant Commissioner for Patents  
Washington, DC 20231

April 4, 2000

Sir:

The following Preliminary Amendments and Remarks are respectfully submitted in connection with the above-identified application.

AMENDMENTS

IN THE SPECIFICATION:

Please amend the specification as follows:

Before line 1, insert --This application is the national phase under 35 U.S.C. § 371 of PCT International Application No. PCT/JP99/04167 which has an International filing date of August 3, 1999, which designated the United States of America.--

REMARKS

The specification has been amended to provide a cross-reference to the previously filed International Application.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By  #32868  
for Gerald M. Murphy, Jr., #28,977

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

GMM/cqc  
230-148P

(Rev. 01/08/2000)

## SPECIFICATION

MUTANT BARNASE GENE AND TRANSGENIC  
PLANT TRANSFORMED BY SAID GENE

The present application claims priority from Japanese Patent Application No.: Hei 10-220060, the disclosure of which is incorporated herein by reference.

## FIELD OF THE INVENTION

This invention relates to a mutant barnase gene which makes it possible to efficiently yield a male sterile transgenic plant when expressed in a specific site of a plant, in particular, anther-specifically. The present invention further relates to a recombinant vector capable of expressing the mutant barnase gene of the invention in host cells, a plant transformed by this vector and a method for constructing a transgenic plant.

## PRIOR ART

Barnase is an RNase originating in *Bacillus amyloliquefaciens* (S. Nishimura and M. Nomura, Biochem. Biophys. Acta 30, 430-431:1958; R.W. Hartley, J. Mol. Biol., 202, 913-915:1988). This enzyme has 110 amino acid residues and hydrolyzes RNA. When expressed in cells, this enzyme inhibits the functions of the cells as a result of its potent RNase activity and thus causes cell death in many cases. By using this characteristic, it is therefore expected that the function of the specific site can be selectively controlled by expressing the barnase gene in a specific site of a plant.

PCT International Publication WO89/10396 discloses a

Casefile Search Results

technique whereby a male sterile plant is obtained by  
constructing a male sterility gene by ligating the above-  
described barnase gene to the downstream of an anther  
tapetal cell-specific expression promoter and introducing  
5 the thus obtained gene into a plant. Male sterilization  
techniques are of great value in efficiently developing an  
F1 hybrid variety.

When the barnase gene is employed as a male sterility  
gene, however, it is frequently observed that resulting male  
10 sterile transgenic plants exhibit unfavorable characteris-  
tics. PCT International Publication WO96/26283 refers to  
this problem in rice. It is also reported that similar  
phenomena are observed not only in rice but in lettuce  
(Scientia Horticulturae 55, 125-139:1993; Arlette Reymaerts,  
15 Hilde Van de Wiele, Greta De Sutter, Jan Janssens:  
Engineered genes for fertility control and their application  
in hybrid seed production). According to this report, a  
plant with depressed activity was constructed by introducing  
a male sterility gene comprising a tobacco anther-specific  
20 promoter (TA29) and a barnase gene into lettuce.

Although reasons for these phenomena have not been  
accurately clarified so far, it is assumed that the so-  
called "position effect" of the site in which the gene is  
transferred may account for the mechanism (PCT International  
25 Publication WO96/26283). More specifically, a desired male  
sterile plant should be constructed if the male sterility  
gene is expressed exclusively in the target site (i.e.,  
anthers). However, there is a possibility that the barnase

might be expressed also in tissues other than anthers although in a very small dose under the action of expression regulators (for example, an endogenous enhancer) existing in the vicinity of the gene transfer site. In such a case, the 5 unfavorable characteristics as described above can appear because barnase has a strong enzymatic activity.

To overcome this problem, the method disclosed in PCT International Publication WO96/26283 exploits the character of cauliflower mosaic virus 35S promoter (hereinafter 10 referred to as CaMV35S promoter) of being expressed potently in tissues other than anthers. Namely, barstar, i.e., an inhibitory protein against barnase is employed therein. The barstar gene ligated to a CaMV35S promoter is transferred into a plant simultaneously with a barnase gene and then the 15 barstar gene is constitutively expressed in tissues other than the anthers, thereby eliminating the effects of the barnase in tissues other than the anthers. However, it is necessary in this method to transfer not only a barnase gene but also a barstar gene, and hence, the problem is that the 20 application of this technique to the breeding of F1 varieties of rice or corn seeds may give rise to a gene silencing. "Gene silencing" is a phenomenon wherein the expression of a gene is inhibited when plural copies of the foreign gene are introduced. It is known that this problem 25 frequently occurs when the expression of a foreign gene is effected by a 35S promoter, though the detailed mechanism thereof has not been clarified yet (R.B. Flavel, Proc. Natl. Acad. Sci. USA 91, 3490-3496:1994; J. Finnegan, Bio.

Technology 12, 883-888:1994; M.A. Matzke and A.J.M. Matzke, Plant Physiol., 107, 679-685:1995). Since, in rice and corn, a barstar gene is used as a "fertility-restoring gene" in the pollen parent (father) so as to allow the pollen in the 5 F1 generation to restore the fertility (C. Mariani, et al., Nature 357, 384-387:1992), if an MS plant (mother) is constructed by the method with the use of a barstar gene as reported in WO96/26283, the F1 plant has plural copies of the barstar gene. In such a case, there is a possibility 10 that the expression of the gene may be inhibited due to the gene silencing.

#### SUMMARY OF THE INVENTION

The present invention provides a method for constructing a male sterile plant by using a barnase gene 15 without resort to a barstar gene.

The present invention further provides a mutant barnase gene to be used in the above method and a process for producing the same.

#### DETAILED DESCRIPTION OF THE INVENTION

20 In the present invention, the DNA sequence of barnase gene (R.W. Hartley, J. Mol. Biol. 202, 913-915:1988) is mutated at least in part and then the thus obtained mutant barnase gene is anther-specifically expressed in a plant so as to make the plant substantially male sterile without any 25 substantially disadvantageous effect on the tissues other than anthers.

The mutation can be performed by a known method such as site-specific mutagenesis, deletion of a fragment by

CABINETS  
SEARCHED  
INDEXED  
SERIALIZED  
FILED

using restriction enzymes or the low fidelity PCR method. Among all, it is preferred to use the low fidelity PCR method. This method is described in detail in D. Leung, E. Chen and D. Goedda, Technique 1, 11-15:1989; Y.Z. 5 Xiaoping and R.H. Ebright, Nucleic Acid Res. 19, 6052:1991; G.C. Rice et al., Proc. Natl. Acad. Sci. USA 89, 5467-5471: 1992 and the contents of these documents are incorporated herein by reference. By using this technique, PCR is carried out under such conditions as to induce some errors 10 during the amplification reaction. Thus, random mutations can be introduced into the target DNA fragment.

Primers to be used in the low fidelity PCR method in the present invention are selected as in the conventional PCR method. It is preferred that each of these primers has 15 a similar number of nucleotides as in the conventional PCR method.

The present inventors performed PCR by using a DNA containing the sequence represented by SEQ ID NO:1 as a template with the use of a combination of primer 1 (5'-  
20 CGTCGGCTC GATGGTACCG GTTATCAACA CGTTGA-3': SEQ ID NO:6) and primer 2 (5'-CCTCTAGATT ATCTGATTT TGAAAGGTC TGATAATG-  
3': SEQ ID NO:7) under such conditions as to induce errors. Thus, a mutant barnase gene having the DNA sequence 25 represented by SEQ ID NO:3 was isolated. The sequence represented by SEQ ID NO:1 employed herein is the sequence of the coding region of the barnase gene contained in the known plasmid pVE108 (WO92/13956). This sequence corresponds to the wild type barnase gene from which the

100-000000-00000000

unnecessary moiety corresponding to the secretion signal in the N-terminal side has been deleted.

It is also possible to acquire different mutant barnase genes by a similar method.

5       The PCR amplification product is cloned in a host (for example, *Escherichia coli*) and clones containing a mutant barnase gene is isolated. In this cloning, clones having a mutant barnase gene may be screened by assaying the RNase activity expressed by the gene. However, it is advantageous 10 to screen the clone by the method consisting of the following two steps by taking advantage of the fact that the RNase activity of barnase affects the growth of *E. coli*.

15      In the first step, a plasmid is prepared by using the mutant barnase gene obtained above and then *E. coli* is transformed thereby. The growth of the *E. coli* transformant thus obtained will be inhibited by the activity of the mutant barnase. Based on this fact, a colony growing slowly (i.e., a small colony), compared with *E. coli* having a control vector free from any barnase gene, is selected. 20 It is expected that the thus selected *E. coli* strain will contain the mutant barnase gene. To confirm that the inhibition of the growth of *E. coli* is due to the expression of the mutant barnase gene, the second step is then carried out.

25      In the second step, a barstar gene is employed. As described above, barstar is an inhibitory protein against barnase. In *E. coli* which expresses barstar, the enzymatic activity of barnase is inhibited and thus the degradation of

mRNA, which otherwise takes place in the presence of barnase, can be inhibited. Therefore if, *E. coli* which expresses a barstar gene is transformed with a barnase gene, the growth will not be inhibited. Accordingly, it is expected that the 5 thus obtained *E. coli* transformant will produce little difference in growth rate from the transformant constructed by the control plasmid which is free from any barnase gene and, therefore, these transformants will produce little difference in colony size too. Based on this principle, a 10 plasmid is prepared from the *E. coli* strain selected in the first step. The plasmid is then used to transform another *E. coli* strain, in which the barstar gene is constitutively expressed. Thus, mutant barnase gene-containing colonies having almost the same size as the one of the *E. coli* 15 transformed by the control plasmid are selected. The *E. coli* with the constitutive expression of the barstar gene to be used herein can be prepared by, for example, the method as will be described in Example 1 hereinafter.

The DNA sequence of the thus obtained mutant barnase 20 gene may be analyzed by a conventional method, if necessary, to thereby examine the mutation in detail.

A preferred example of the mutant barnase gene of the present invention is one which has the DNA sequence represented by SEQ ID NO:3. Compared with the nucleotide 25 sequence of SEQ ID NO:1 coding for the wild type activity, the nucleotide sequence encoding this gene has an insertion of "T" at the 15-position from A in the initiation codon ATG and a deletion of "A" at the 333-position. According to the

064304-000000000000

normal translation manner, translation will be initiated from ATG at the 1-position of this DNA sequence represented by SEQ ID NO:3, and terminated at the ninth codon which has been converted to a termination codon as a result of the 5 insertion of the "T" at the 15-position. It is unlikely that the thus formed oligopeptide consisting of 8 amino acids has the barnase activity. Further, there is no other ATG or GTG codon from which the translation can be initiated in the correct frame in the vicinity thereof. However, the 10 fact that the growth rate of *E. coli* was restored by the barstar protein strongly suggests that the translation of the barnase protein from the gene of SEQ ID NO:3 proceeded in the correct frame. This is seemingly due to a phenomenon called "frame shift re-coding" whereby the ribosome controls 15 the translation while automatically shifting the reading frame during the course of translation into the protein. This phenomenon, which has been reported in several genes of viruses, *E. coli* and animals, generally depends exclusively on an individual nucleotide sequence and neither any special 20 protein nor translation device is required. The frame shifting efficiency during the translation varies from gene to gene, i.e., ranging from several % to 50%. In the case of the mutant barnase gene, it is considered that the efficiency of the shifting of the reading frame during the 25 translation is not high and thus the translation product in the correct frame is formed in a smaller amount, thereby lowering the activity of the gene.

Moreover, there is a high possibility that other

mutant barnase genes of which the translation efficiency is lowered due to the shifting of the reading frame, as in the case of the DNA sequence represented by SEQ ID NO:3, or some other reasons can be obtained by mutating the barnase gene 5 by, for example, the low fidelity PCR method. Furthermore, there is a high possibility that a gene having a DNA sequence derived from the DNA sequence represented by SEQ ID NO:3 by substitution, deletion, insertion or addition of one or more nucleotides will be a mutant barnase gene which 10 provides a lowered translation efficiency due to the shifting of the reading frame as a result of the insertion of T at the 15-position from A in the initiation codon ATG and/or the deletion of A at the 333-position, as in the DNA sequence represented by SEQ ID NO:3. It is considered that 15 each of these genes, likewise the gene of SEQ ID NO:3, is capable of making a plant substantially male sterile when it is anther-specifically expressed in the plant. Accordingly, these genes are also included in the scope of the present invention similar to the gene of SEQ ID NO:3.

20 The plant which is to be male sterilized by the mutant barnase gene is not particularly limited, so long as the gene can be transferred into the plant to provide a male sterilized plant. Examples of the plants include rice, corn, tobacco, lettuce and Brassica. Among all, rice and corn are 25 preferred.

In order to male sterilize a plant, the mutant barnase gene is expressed specifically in the anthers of the plant to inhibit the anther functions by the RNase activity of

barnase. Such an anther-specific expression can be achieved by using the method described in WO92/13957. In brief, the mutant barnase gene is ligated to the downstream of an anther-specific promoter and then incorporated into plant 5 cells with the use of an expression vector.

The incorporation may be performed by using the Agrobacterium method, the electroporation method, the particle gun method, etc.

From the transformed plant cells, a complete plant can 10 be formed by the regeneration from a callus of the transformed plant cells in accordance with, for example, the method reported in Y. Hiel et al., Plant J. 6, 271-282:1994.

The male sterility of the thus constructed plant can be confirmed by the inability of the plant to fertilize 15 unless it is pollinated from another fertilizable plant.

Example 1: Preparation of mutant barnase gene

Low fidelity PCR

Primer 1 (CGTTCGGCTC GATGGTACCG GTTATCAACA CGTTTGA: SEQ ID NO:6) and Primer 2 (CCTCTAGATT ATCTGATTTC TGTAAGGTC 20 TGATAATG: SEQ ID NO:7) were synthesized by a DNA synthesizer (manufactured by Applied Biosystems) in accordance with the method described in S.L. Beaucage et al., Tetrahedron Lett., 22. 1859-1862:1982. Known plasmid pVE108 (WO92/13956) was used as a template and PCR was carried out with the use of 25 the combination of Primers 1 and 2. SEQ ID NO:1 shows the sequence of the coding region of the barnase gene which is contained in pVE108. The reaction was performed for 50 cycles with each cycle consisting of 1 minute at 94°C,

1 minute at 57°C and 1 minute at 72°C in 10 mM Tris-HCl (pH 9.5), 50 mM KCl, 2 mM MgCl<sub>2</sub>, and 1 mM each of dNTP, 10 ng of the template DNA and 0.5 U of Taq DNA polymerase.

After the completion of the reaction, the amplification product was separated by electrophoreses on agarose gel (2% SeaKem GTG agarose, 1xTAE) and purified by the DEAE-cellulose method (M. Muramatsu, Labo-manual Idenshikogaku (Gene Engineering Labo-Manual), Maruzen, pp.111:1988). By using the purified product thus obtained as a template, PCR was performed again under the conditions as defined above.

Ligation of mutated barnase gene fragment into plasmid vector

The reaction product from the above step was digested with SacI and XbaI in a conventional manner and then purified by agarose gel electrophoresis to give an "insertion fragment". A plasmid to be used for transferring this insertion fragment into *E. coli* can be appropriately selected. For example, use may be made of plasmid pHM1 therefor. The plasmid pHM1 was constructed as follows.

Plasmid pBR322 was cleaved at the EcoRI site and blunt-ended by using T4 DNA polymerase (manufactured by Takara Shuzo). Separately, lacZ expression cassette (322 bp) was excised from pUC18 with Pvull and the ends thereof were blunted. The cassette was integrated into the restriction site of the blunt-ended plasmid pBR 322 to give plasmid pHM1.

Plasmid pHM1 was digested with SacI and XbaI followed by dephosphorylation with calf intestine alkaline phosphatase (manufactured by Takara Shuzo) to give a

restriction enzyme-treated plasmid fragment. Into this restriction enzyme-treated plasmid pHM1, the above "insertion fragment" containing a barnase gene was ligated by using Takara Ligation Kit ver.1 (manufactured by Takara 5 Shuzo).

Introduction into *E. coli* and selection of barnase-active clone

The *E. coli* having the barnase gene introduced thereinto may be selected by, for example, the following 10 method. Since mRNA is degraded in cells by the barnase activity, the synthesis of protein is suppressed and, in its turn, the growth of *E. coli* is inhibited. Thus, the *E. coli* transformed by the barnase gene can be selected by taking advantage of the fact that the desired transformant colony 15 has a smaller size than the *E. coli* colony transformed by the control plasmid free from the mutant barnase gene. When the wild type barnase or a mutant barnase still maintaining the activity comparable thereto is integrated into pHM1, *E. coli* cannot form any colony. Thus, clones having a 20 sufficiently weakened barnase activity can be exclusively selected.

Thus, the plasmid having the mutant barnase gene ligated thereto was precipitated from ethanol and then introduced into *E. coli* LE392 strain by the electroporation 25 method with the use of GenePulser (BioRad) in accordance with the manufacturer's instruction. Also, the control plasmid free from mutant barnase was introduced into the *E. coli* LE392 strain in the same manner.

Next, these *E. coli* transformants were plated onto an LB agar medium containing tetracycline (25 µg/ml) and incubated at room temperature (25°C) for 72 hours. Then colonies of a smaller size than the colony of *E. coli* having 5 the control plasmid pHM1 introduced thereinto were screened as colonies of the *E. coli* transformants having the mutant barnase transferred thereinto (Table 1, A).

Selection of mutant barnase clone by barstar gene

As described above, barstar is an enzyme acting as an 10 antagonist to barnase. In *E. coli* wherein barstar is expressed, the enzymatic activity of barnase is inhibited and thus the degradation of mRNA, which otherwise takes place in the presence of barnase, can be inhibited. Therefore, if *E. coli* expressing barstar is transformed by a 15 plasmid containing a barnase gene, the growth thereof will not be inhibited. Accordingly, it is expected that the thus obtained *E. coli* transformant will show little difference in growth rate from the transformant constructed by using the control plasmid free from a barnase gene and, therefore, 20 these transformants will show little difference in colony size too.

An *E. coli* transformant which expressed barstar was constructed in the following manner. A barstar gene described in R.W. Hartley, J. Mol. Biol. 202, 913-915:1998 25 was excised with HindIII and XbaI and ligated in frame to a tac promoter (de Boer et al., Proc. Natl. Acad. Sci. USA 80, 21-25:1983). The gene, together with a chloramphenicol tolerance gene (N.K. Alton and D. Vapnek, Nature 282, 864-

869:1979), was ligated into the defective transposon which lacked the transferase in a vector described in Herrero et al., J. Bacteriol. 172, 6557-6567:1990. Subsequently, the thus obtained plasmid was introduced into *E. coli* MC1061  
5 strain thereby to transfer the transposon, which contained the barstar gene cassette, into the chromosome of the *E. coli*. It was confirmed based on the chloramphenicol tolerance that this *E. coli* was able to maintain the barstar gene cassette in a stable state. Since the *E. coli* MC1061  
10 strain lacked the lacI gene, the tac promoter was continuously active and thus the barstar gene was constitutively expressed.

The plasmid containing the mutant barnase gene as the insertion fragment and the control plasmid free from the same were each introduced into the above *E. coli* transformant by the electroporation method. Then the *E. coli* transformants were plated onto an LB agar medium containing IPTG (1mM) and tetracycline (25 µg/ml) and incubated at 25°C for 72 hours. Among the colonies of the *E. coli* transformed  
15 by the mutant barnase gene, a colony being comparable in size to the colony of the *E. coli* having the control plasmid pHM1, which had been simultaneously plate-cultured, was  
20 screened and named "#4-31" (Table 1, B).

Table 1: Screened clone and colony size (mm)

	Screened clone	pHM1 (control)
A: <i>E. coli</i> LE392 <sup>*1</sup>	1.77 ± 0.33	2.65 ± 0.47
B: <i>E. coli</i> with barstar gene expression <sup>*2</sup>	1.39 ± 0.10	1.55 ± 0.08

\*1: Colony size after incubation on the LB agar plate containing 25 µg/mL of tetracycline at 28°C for 48 hours.

5 \*2: Colony size after incubation on the LB agar plate containing 25 µg/mL of tetracycline at 28°C for 24 hours.

Example 2: Determination of nucleotide sequence of mutant barnase gene

10 From the *E. coli* screened in Example 1, a cloned mutant barnase gene appropriate for the object of the present invention was prepared. First, the clone #4-31 screened in Example 1 was propagated. Next, the mutant barnase gene fragment in the clone #4-31 was excised with  
15 KpnI and XbaI and ligated into the KpnI, XbaI-site of pUC119 having been cleaved similarly with KpnI and XbaI. After amplifying the obtained plasmid by using *E. coli*, a reaction was performed by the cycle sequence method with the use of Taq polymerase (Taq Dye Terminator Cycle Sequencing Kit,  
20 manufactured by Applied Biosystems Inc.) in accordance with the manufacturer's protocol. Subsequently, the sequence was analyzed with a DNA Sequencer (Model 373A, manufactured by Applied Biosystems Inc.), thereby yielding the sequence represented by SEQ ID NO:3. Compared with the DNA sequence

of the wild type barnase gene, this sequence had an insertion of T at the 15-position from A of the initiation codon ATG and a deletion of A at the 333-position.

Example 3: Construction of male sterile rice by using  
5   attenuated mutant barnase gene

The attenuated mutant barnase gene integrated into pUC119 as described above was cleaved with restriction enzymes XbaI and KpnI and thus the plasmid vector pTS431 represented by SEQ ID NO:5 was constructed. Although this 10 plasmid pTS431 differs from the known plasmid pVE108 (PCT International Publication WO92/13956) in the following points, it is substantially equivalent thereto except for the moieties of the anther-specific promoter and the mutant barnase.

15       (1) In the plasmid vector pTS431 according to the present invention, the barnase gene (SEQ ID NO:1) in the known plasmid pVE108 has been converted into the mutant barnase gene (SEQ ID NO:3).

20       (2) A tobacco-origin anther specific promoter is used in the known plasmid pVE108, while the anther specific promoter of rice E1 gene (PCT International Publication WO92/13956) is used in the plasmid vector pTS431 according to the present invention.

25       (3) In the present invention, a 35S3 promoter (EP 0344029) of 1376 bp, which is not used in the plasmid pVE108, is employed upstream of the barnase gene.

      (4) In the present invention, a sequence originating in the downstream of Agrobacterium T-DNA gene 7 excised from

pJD884 (PCT International Publication WO93/09218) is employed whereas such a sequence is not used in the plasmid pVE108.

(5) In the present invention, the region corresponding 5 to lacZ has been deleted from the pUC19-origin moiety. In addition a plasmid (pTS172) having the wild type barnase gene integrated therein is represented by SEQ ID NO:4.

The fragment of about 4.5 kbp was excised with a restriction enzyme EcoRI respectively from pTS431 (a plasmid 10 having the mutant barnase gene transferred thereinto; SEQ ID NO:5) and pTS172 (a plasmid having the barnase gene transferred thereinto; SEQ ID NO:4) and inserted into the EcoRI-site of the intermediate vector pSB11 (T. Komari et al., Plant J. 10(1), 165-174:1996), and further, the T-DNA 15 region thereof was integrated into the acceptor vector pSB1 (T. Komari et al., Plant J. 10(1), 165-174:1996) by way of homologous recombination. By using *Agrobacterium* 20 *tumefaciens* LBA4404 having the obtained recombinant plasmids (pSB1431 and pSB1172 respectively), rice (variety: Asanohikari) was transformed. While the transformation was performed basically in accordance with the method of Hiei et al. (Plant J. 6(2), 271-282:1994), phosphinothricine 25 (concentration: 10 mg/L) was employed for screening transformants since the thus constructed male sterility genes contained bar gene encoding phosphinithricine acetyl transferase as a selective marker. Phosphinothricine facilitates selection of calluses having the gene transferred thereinto.

A comparison of the rice transformant obtained with the use of the wild type barnase gene with the one obtained with the use of the mutant barnase gene indicates that the transfer of the mutant barnase gene gave rise to a remarkable improvement in the transformation efficiency and an increase in the rate of morphologically normal male sterility transformants, as shown in Table 2.

Table 2: Transformation efficiency

	No. of infected calluses	No. of regenerated calluses	No. of PCR-positive lines <sup>*1</sup>	No. of morphologically normal male sterile lines
pSB1172 (control)	2838	83	52/83	9/52(17.3%)
pSB1431 (present invention)	787	69	43/45 <sup>*2</sup>	27/28 <sup>*3</sup> (96.4%)

\*1: detection of barnase gene fraction by PCR.

\*2: examined only 45 lines among 69.

\*3: examined only 28 lines among 43.

#### Effects of the Invention

In the present invention, a barnase gene having a weakened effect is constructed via mutation. A male sterility gene comprising the mutant barnase gene can be introduced into a plant to successfully produce a male sterile plant free from any unfavorable characteristic at a high efficiency with the use of a single gene without resort to the use of a barstar gene.

CLAIMS

1. A mutant barnase gene having one or some mutations at least in part of the DNA sequence of barnase gene, wherein said mutant barnase gene is capable, when anther-specifically expressed in a plant, of making said plant substantially male sterile without exerting any substantially disadvantageous effect on the tissues except for the anthers.
2. The gene as claimed in Claim 1, wherein said mutation is a mutation causing frame shift re-coding.
3. A gene which is derived from a DNA sequence encoding the same amino acid sequence as shown in SEQ ID NO:1 by substitution, deletion, insertion or addition of one to several nucleotides in said DNA sequence, wherein said gene is capable of encoding a protein which makes a plant substantially male sterile when expressed anther-specifically in said plant.
4. A gene comprising a DNA sequence which is derived from a DNA sequence encoding the same amino acid sequence as shown in SEQ ID NO:1 by substitution, deletion, insertion or addition of one to several nucleotides in the latter DNA sequence, and a promoter located upstream of said DNA sequence for allowing an anther-specific expression, wherein said gene is capable of making a plant substantially male sterile when introduced into the genome of said plant.
5. A gene represented by SEQ ID NO:3 which encodes a protein capable of making a plant substantially male sterile when expressed anther-specifically in said plant.

6. A gene comprising the sequence represented by SEQ ID NO:3 and a promoter located upstream of said sequence for allowing an anther-specific expression, wherein said gene is capable of making a plant substantially male sterile when introduced into the genome of said plant.

7. A recombinant vector which contains a gene as claimed in any of Claims 1 to 6 and expresses said gene in a host plant.

8. A method of making a plant male sterile which comprises transforming said plant by a mutant barnase gene as claimed in any of Claims 1 to 6 and allowing said mutant barnase gene to be expressed anther-specifically.

9. The method as claimed in Claim 8, wherein said plant is transformed by said mutant barnase gene by integrating said gene into the genome of said plant.

10. A transgenic plant wherein a gene as claimed in any of Claims 1 to 6 has been introduced.

## ABSTRACT

A male sterile plant free from any undesirable characteristic is constructed by anther-specifically expressing barnase gene alone. A barnase gene, which has a 5 mutation and thus sustains its activity at a lowered level, is transferred into a plant and anther-specifically expressed, thereby efficiently providing a male sterile transgenic plant.

## BIRCH, STEWART, KOLASCH &amp; BIRCH, LLP

## COMBINED DECLARATION AND POWER OF ATTORNEY

ATTORNEY DOCKET NO.

230-148P

## FOR PATENT AND DESIGN APPLICATIONS

PLEASE NOTE:  
YOU MUST  
COMPLETE THE  
FOLLOWING:

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated next to my name; that I verily believe that I am the original, first and sole inventor (if only one inventor is named below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Insert Title: **MUTANT BARNASE GENE AND TRANSGENIC PLANT TRANSFORMED BY SAID GENE**

Fill in Appropriate Information - For Use Without Specification Attached: the specification of which is attached hereto. If not attached hereto, the specification was filed on \_\_\_\_\_ as United States Application Number \_\_\_\_\_; and /or the specification was filed on August 3, 1999 as PCT International Application Number PCT/JP99/04167; and was amended under PCT Article 19 on \_\_\_\_\_ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I do not know and do not believe the same was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to this application, that the same was not in public use or on sale in the United States of America more than one year prior to this application, that the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months (six months for designs) prior to this application, and that no application for patent or inventor's certificate on this invention has been filed in any country foreign to the United States of America prior to this application by me or my legal representatives or assigns, except as follows.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Insert Priority Information: (if appropriate)	Prior Foreign Application(s)			Priority Claimed
	220060/1998 (Number)	Japan (Country)	8/4/1998 (Month/Day/Year Filed)	
	_____	_____	_____	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
	_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
	_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
	_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
	_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No

Insert Provisional Application(s): (if any) I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

(Application Number)	(Filing Date)
_____	_____

Insert Requested Information: (if appropriate) All Foreign Applications, if any, for any Patent or Inventor's Certificate Filed More Than 12 Months (6 Months for Designs) Prior To The Filing Date of This Application:

Country	Application No.	Date of Filing (Month/Day/Year)
_____	_____	_____

Insert Prior U.S. Application(s): (if any) I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Number)	(Filing Date)	(Status - patented, pending, abandoned)
_____	_____	_____

I hereby appoint the following attorneys to prosecute this application and/or an international application based on this application and to transact all business in the Patent and Trademark Office connected therewith and in connection with the resulting patent based on instructions received from the entity who first sent the application papers to the attorneys identified below, unless the inventor(s) or assignee provides said attorneys with a written notice to the contrary:

Terrell C. Birch	(Reg. No. 19,382)	Raymond C. Stewart	(Reg. No. 21,066)
Joseph A. Kolasch	(Reg. No. 22,463)	James M. Slattery	(Reg. No. 28,380)
Bernard L. Sweeney	(Reg. No. 24,448)	Michael K. Mutter	(Reg. No. 29,680)
Charles Gorenstein	(Reg. No. 29,271)	Gerald M. Murphy, Jr.	(Reg. No. 28,977)
Leonard R. Svensson	(Reg. No. 30,330)	Terry L. Clark	(Reg. No. 32,644)
Andrew D. Meikle	(Reg. No. 32,868)	Marc S. Weiner	(Reg. No. 32,181)
Joe McKinney Muncy	(Reg. No. 32,334)	Andrew F. Reish	(Reg. No. 33,443)
C. Joseph Faraci	(Reg. No. 32,350)	Donald J. Daley	(Reg. No. 34,313)

Send Correspondence to:

**BIRCH, STEWART, KOLASCH & BIRCH, LLP**

P.O. Box 747 • Falls Church, Virginia 22040-0747

Telephone: (703) 205-8000 • Facsimile: (703) 205-8050

PLEASE NOTE:  
YOU MUST  
COMPLETE THE  
FOLLOWING:

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of First or Sole Inventor: Insert Name of Inventor Insert Date This Document is Signed	GIVEN NAME <u>Kazuyuki</u>	FAMILY NAME <u>HAMADA</u>	INVENTOR'S SIGNATURE <i>Kazuyuki Hamada</i>	DATE* <u>March 13, 2000</u>
Insert Residence Insert Citizenship	Residence (City, State & Country) <u>Shizuoka, Japan</u>		CITIZENSHIP <u>Japanese</u>	
Insert Post Office Address	POST OFFICE ADDRESS (Complete Street Address including City, State & Country) c/o Japan Tobacco Inc., Plant Breeding and Genetics Research Laboratory, 700, Higashibara, Toyoda-cho, Iwata-gun, Shizuoka 438-0802 Japan			
Full Name of Second Inventor, if any see above	GIVEN NAME <u>Fumio</u>	FAMILY NAME <u>NAKAKIDO</u>	INVENTOR'S SIGNATURE <i>Fumio Nakakido</i>	DATE* <u>March 13, 2000</u>
	Residence (City, State & Country) <u>Shizuoka, Japan</u>		CITIZENSHIP <u>Japanese</u>	
	POST OFFICE ADDRESS (Complete Street Address including City, State & Country) c/o Japan Tobacco Inc., Plant Breeding and Genetics Research Laboratory, 700, Higashibara, Toyoda-cho, Iwata-gun, Shizuoka 438-0802 Japan			
Full Name of Third Inventor, if any see above	GIVEN NAME	FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
	Residence (City, State & Country)		CITIZENSHIP	
	POST OFFICE ADDRESS (Complete Street Address including City, State & Country)			
Full Name of Fourth Inventor, if any see above	GIVEN NAME	FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
	Residence (City, State & Country)		CITIZENSHIP	
	POST OFFICE ADDRESS (Complete Street Address including City, State & Country)			
Full Name of Fifth Inventor, if any see above	GIVEN NAME	FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
	Residence (City, State & Country)		CITIZENSHIP	
	POST OFFICE ADDRESS (Complete Street Address including City, State & Country)			

\* DATE OF SIGNATURE

09/509945  
527 Rec'd PCT/PTO 04 APR 2000

SEQUENCE LISTING

<110> Japan Tobacco Inc.

<120> MUTANT BARNASE GENE AND TRANSGENIC PLANT TRANSFORMED BY SAID GENE

<130> 980687

<160> 7

<210> 1

<211> 343

<212> DNA

<213> Bacillus amyloliquefaciens

<220>

<221> NAME/KEY: CDS

<222> 1..336

<400> 1

atg gta ccg gtt atc aac acg ttt gac ggg gtt gcg gat tat ctt cag 48

Met Val Pro Val Ile Asn Thr Phe Asp Gly Val Ala Asp Tyr Leu Gln

1 5 10 15

aca tat cat aag cta cct gat aat tac att aca aaa tca gaa gca caa 96

Thr Tyr His Lys Leu Pro Asp Asn Tyr Ile Thr Lys Ser Glu Ala Gln

20 25 30

gcc ctc ggc tgg gtg gca tca aaa ggg aac ctt gca gac gtc gct ccg 144

Ala Leu Gly Trp Val Ala Ser Lys Gly Asn Leu Ala Asp Val Ala Pro

35 40 45

ggg aaa agc atc ggc gga gac atc ttc tca aac agg gaa ggc aaa ctc 192

Gly Lys Ser Ile Gly Gly Asp Ile Phe Ser Asn Arg Glu Gly Lys Leu

50	55	60	
ccg ggc aaa agc gga cga aca tgg cgt gaa gcg gat att aac tat aca			
Pro Gly Lys Ser Gly Arg Thr Trp Arg Glu Ala Asp Ile Asn Tyr Thr			
65	70	75	80
tca ggc ttc aga aat tca gac cg att ctt tac tca agc gac tgg ctg			
Ser Gly Phe Arg Asn Ser Asp Arg Ile Leu Tyr Ser Ser Asp Trp Leu			
85	90	95	
att tac aaa aca acg gac cat tat cag acc ttt aca aaa atc aga taa			
Ile Tyr Lys Thr Thr Asp His Tyr Gln Thr Phe Thr Lys Ile Arg			
100	105	110	
ggtaacc			
343			
<210> 2			
<211> 112			
<212> PRT			
<213> <u>Bacillus amyloliquefaciens</u>			
<400> 2			
Met Val Pro Val Ile Asn Thr Phe Asp Gly Val Ala Asp Tyr Leu Gln			
1	5	10	15
Thr Tyr His Lys Leu Pro Asp Asn Tyr Ile Thr Lys Ser Glu Ala Gln			
20	25	30	
Ala Leu Gly Trp Val Ala Ser Lys Gly Asn Leu Ala Asp Val Ala Pro			
35	40	45	
Gly Lys Ser Ile Gly Gly Asp Ile Phe Ser Asn Arg Glu Gly Lys Leu			
50	55	60	
Pro Gly Lys Ser Gly Arg Thr Trp Arg Glu Ala Asp Ile Asn Tyr Thr			
65	70	75	80
Ser Gly Phe Arg Asn Ser Asp Arg Ile Leu Tyr Ser Ser Asp Trp Leu			

85 90 95  
Ile Tyr Lys Thr Thr Asp His Tyr Gln Thr Phe Thr Lys Ile Arg  
100 105 110

<210> 3  
<211> 342  
<212> DNA  
<213>

<400> 3  
atggtaacgg ttattcaaca cgtttgcacgg ggttgcggat tatcttcaga catatcataa 60  
gctacctgat aattacatta caaaatcaga agcacaagcc ctggctggg tggcatcaaa 120  
agggaacctt gcagacgtcg ctccgggaa aagcatcgcc ggagacatct tctcaaacag 180  
ggaaggcaaa ctcccggca aaagcggacg aacatggcgt gaagcggata ttaactatac 240  
atcaggcttc agaaattcag accggattct ttactcaagc gactggctga tttacaaaac 300  
aacggaccat tatcagacacct ttacaaaaat cagtaatcta ga 342

<210> 4  
<211> 6548  
<212> DNA  
<213> Escherichia coli LE392  
<220>  
<223> Clone: pTS172

<400> 4  
aattcaagct tgacgtcagg tggcactttt cggggaaatg tgcgcggAAC ccctatTTGT 60  
ttatTTTCT aaatacattc aaatatgtat ccgctcatga gacaataacc ctgataaaatg 120  
cttcaataat attgaaaaAG gaagagtatg agtattcaac atttccgtgt cgcccttatt 180  
ccctttttg cggcattttg cttccctgtt ttgctcacc cagaaacgct ggtgaaagta 240

aaagatgctg aagatcagtt gggcacga gtgggttaca tcgaactgga tctcaacagg  
ggtaagatcc ttgagagttt tcgccccaa gaacgttttcaatgatgag cactttaaa  
gttctgctat gtggcgccgtt attatcccgtt attgacgcccggcaagagca actcggtcg  
cgcatacactt attctcagaa tgacttggtt gagtactcac cagtcacaga aaagcatctt  
acggatggca tgacagtaag agaattatgc agtgcgtccaa taaccatgag tgataacact  
gcggccaact tacttctgac aacgatcgga ggaccgaagg agctaaccgc tttttgcac  
aacatggggg atcatgtAAC tcgccttgat cggtggaaac cgtagctgaa tgaagccata  
ccaaacgacg agcgtgacac cacgatgcctt gtagcaatgg caacaacgtt gcgc当地  
ttaactggcg aactacttac tctagttcccgcaacaat taatagactg gatggaggcg  
gataaagttt caggaccact tctgcgtcg gcccttccgg ctggctggtt tattgctgat  
aaatctggag ccggtgagcg tgggtctcg ggtatcattt cagcactggg gccagatgg  
aagccctccc gtatcgtagt tatctacacg acggggagtc aggcaactat ggatgaacga  
aatagacaga tcgctgagat aggtgcctca ctgattaagc attggtaact gtcagaccaa  
gtttactcat atatacttta gattgattta aaacttcattt ttaattttaa aaggatctag  
gtgaagatcc ttttggctc gagtctcatg accaaaatcc cttaacgtga gtttcgttc  
cactgagcgtt cagacccgtt agaaaaagatc aaaggatctt cttgagatcc ttttttctg  
cgctaatctt gctgcttgca aaaaaaaaaa ccaccgctac cagcggtggt ttgtttgccg  
gatcaagagc taccaactctt tttccgaag gtaactggct tcagcagagc gcagatacca  
aatactgtcc ttctagtgtt gccgttagttt ggccaccact tcaagaactc tgttagcacc  
cctacatacc tcgctctgctt aatcctgtt ccagtggctg ctgccagtgg cgataagtcg  
tgtcttaccg ggttggactc aagacgatag ttaccggata aggccgacgc gtcgggctga  
acgggggggtt cgtgcacaca gcccagctt gaggcaacga cctacaccga actgagatac  
ctacagcgtt agcattgaga aagcgccacg cttcccgaaag ggagaaaggc ggacaggtat  
ccggtaagcg gcagggtcgaa acaggagag cgcacgaggg agcttccagg gggaaacgcc  
tggtatctt atagtcctgtt cgggttcgc cacctctgac ttgagcgtcg atttttgc  
tgctcgtcag gggggcggag cctatggaaa aacgccagca acgcggcctt ttacgggt  
ctggcccttt gctggccctt tgctcacatg ttcttcctg cgatccccc tgattctgt  
gataaccgtt ttaccgcctt tgagttagt gataccgctc gccgcagccg aacgaccgag  
cgccagcgtt cagttagcga ggaaggcggaa gagcgc当地 accgc当地 accgc当地

gcgcggtggc ctgatcagaa ttcatatgca cgtgttccc atctagtaac atagatgaca 2040  
ccgcgcgca taatttatcc tagttgcgc gctatattt gtttctatc gcgtattaaa 2100  
tgtataattg cgggactcta atcataaaaa cccatctcat aaataacgac atgcattaca 2160  
tgttaattat tacatgctta acgtaattca acagaaattt tatgataatc atcgcaagac 2220  
cggaacagg attcaatctt aagaaacttt attgccaat gtttgaacga tctgcttcgg 2280  
aggttacctt atctgatttt tgtaaaggc tgataatggt ccgttggtt gtaaatcagc 2340  
cagtcgctt agtaaagaat ccggctgaa tttctgaagc ctgatgtata gtaatatcc 2400  
gcttcacgcc atgttcgtcc gctttgccc gggagttgc cttccctgtt tgagaagatg 2460  
tctccgccga tgctttccc cgaggcgacg tctgcaaggt tccctttga tgccacccag 2520  
ccgaggcctt gtgcttctga tttttaatg taattatcag gtagctttag atatgtctga 2580  
agataatccg caaccccgtc aaacgtttg ataaccgta ccatcgac ggcttgatgg 2640  
atctctgct ggacaccggg atgctaggat gggttatcgt ggccggcgtg cgtgtgtggc 2700  
tttttaggc gccggcgacg gcggggcaa tgtggcaggt gagtcacggt gcaagcgtgc 2760  
gcaagtgact gcaacaacca aggacggta tggcggaaagc acctcacgac tccaccgtct 2820  
acaggatgta gcagtagcac ggtgaaagaa gtgttgtccc gtccatttagg tgcattctca 2880  
ccgttggcca gaacaggacc gttcaacagt taggtagt gtaggacttt tacgtggta 2940  
atgtatggca aatagtagta aatttgccc ccattggtct ggctgagata gaacatattc 3000  
tggaaagcct ctagcatatc tttttgaca gctaaacttt gcttctgcc ttcttggct 3060  
agcaatgacg ttgccccatgt cgtggaaac atctggtaag gtaactgtat tcgtttgttc 3120  
ccttcaacgg ctcaatcccc acaggccaag ctatccttc cttggcagta taggctccct 3180  
gagagattt actaccattt ttaagtgcct ataaagacga tgctctctaa ccagatcgat 3240  
cagaaacaca aagtttagc agcgtaatat cccacacaca tacacacacg aagctatgcc 3300  
tcctcatttt ccgagagatt ctgacagtga ccagaatgtc agaatgccat ttcatggca 3360  
caagtcgatc cacaagcttc ttggggagg tcaagggtgtc ctattattat tcgctttcta 3420  
ggaaattatt cagaatttagt gcctttatc ataacttctc tctgagccga tgtggtttg 3480  
gatttcattt tgggagcta tgcagttgcg gatattctgc tgtggaaagaa caggaactt 3540  
tctgcgggg tccttgctgg ggcaacattt atatggttcc tggtcgatgt agtagaaatc 3600  
aatataattc cgctccctt ccagattgcc attcttgcca tgcttgatgt ctccatttgg 3660  
tcaaatgccg caccactt ggacaggtat tagcttatt tcctgtggag atggtagaaa 3720

actcagctta cagaaatggc atttcacgta gtataacgca agacattagg tactaaaact 3780  
caactaactg tttccgaatt tcagggcccc tccaaggatc ccagaatca tcatctctga 3840  
acatgccttc agagaaatgg cattgaccgt ccattacaaa ctaacgtaca ctgtatctgt 3900  
tctttacgac attgcatgtg gaaaggatct gaagagattt ctccgttac ataataatct 3960  
actccttgcc tacgttaata agagatgtaa aaacatgca cagttccagt gccaacattg 4020  
tccaaggatt gtgcaattct ttctggagcg ctaaaattga ccagattaga cgcatcagaa 4080  
tattgaattt cagagtttgc caataatcct cataatgtt atgtgttattt gtttttact 4140  
actcaatata gttctggact aacaatcaga ttgttatga tattaagggtt gttggatctc 4200  
tattggattt gtcggcgatt ggaagtttctt gcagcttgac aagtctacta tatattggta 4260  
ggttattccag ataaatatta aattttataa aaacaatcac acagaaggat ctgcggccgc 4320  
tagccttaggc ccgggcccac aaaaatctga gcttaacagc acagttgctc ctctcagagc 4380  
agaatcgggtt attcaacacc ctcatatcaa ctactacgtt gtgtataacg gtccacatgc 4440  
cggttatatac gatgactggg gttgtacaaa ggcggcaaca aacggcggtc ccggagttgc 4500  
acacaagaaa ttgccacta ttacagaggc aagagcagca gctgacgcgt acacaacaag 4560  
tcagcaaaca gacaggttga acttcatccc caaaggagaa gctcaactca agcccaagag 4620  
ctttgctaag gccctaacaa gcccacaaaa gcaaaaagcc cactggctca cgcttaggaac 4680  
caaaaggccc agcagtgtatc cagccccaaa agagatctcc ttggcccg agattacaat 4740  
ggacgatttc ctctatctt acgatctagg aaggaagttc gaaggtgaag gtgacgacac 4800  
tatgttcacc actgataatg agaaggtagt cctcttcaat ttcatggaaaga atgctgaccc 4860  
acagatggtt agagaggcct acgcagcagg tctcatcaag acgatctacc cgagtacaa 4920  
tctccaggag atcaaatacc ttcccaagaa gttaaagat gcagtcaaaa gattcaggac 4980  
taattgcatc aagaacacag agaaagacat atttctcaag atcagaagta ctattccagt 5040  
atggacgattt caaggcttgc ttccataaacc aaggcaagta atagagattt gagttttca 5100  
aaaggtagtt cctactgaat ctaaggccat gcatggagtc taagattcaa atcgaggatc 5160  
taacagaact cggcggtgaag actggcgaac agttcataca gagttttta cgactcaatg 5220  
acaagaagaa aatcttcgtc aacatggtgg agcacgacac tctggtctac tccaaaaatg 5280  
tcaaagatac agtctcagaa gaccaaagggtt ctattgagac ttttcaacaa aggataattt 5340  
cgggaaacctt cctcggttccatttgc cttcatcgaa aggacagtag 5400  
aaaaggaagg tggctcctac aaatgccatc attgcataa aggaaaggct atcattcaag 5460

atgcctctgc cgacagtggc cccaaagatg gaccccccacc cacgaggagc atcggtggaaa 5520  
aagaagacgt tccaaaccacg tcttcaaagc aagtggattt atgtgacatc tccactgacg 5580  
taaggatga cgccacaatcc cactatcctt cgcaagaccc ttccctctata taaggaagtt 5640  
catttcattt ggagaggaca cgctgaaatc accagtctct ctctataaat ctatctct 5700  
ctctataacc atggacccag aacgacgccc ggccgacatc cgccgtgccca ccgaggcgga 5760  
catgccggcg gtctgcacca tcgtcaacca ctacatcgag acaagcacgg tcaacttccg 5820  
taccgagccg caggaaccgc aggagtggac ggacgaccc gtccgtctgc gggagcgcta 5880  
tccctggctc gtcgcccagg tggacggcga ggtcgccggc atgcctacg cggccccctg 5940  
gaaggcacgc aacgcctacg actggacggc cgagtcgacc gtgtacgtct ccccccggcca 6000  
ccagcggacg ggactgggct ccacgctcta caccacactg ctgaagtccc tggaggcaca 6060  
gggcttcaag agcgtggtcg ctgtcatcg gctgccaaac gacccgagcg tgccatgca 6120  
cgaggcgctc gatatgccc cccgcggcat gctgcggcggc gccggcttca agcacgggaa 6180  
ctggcatgac gtgggtttct ggcagctgga cttcagcctg ccggtaccgc cccgtccgg 6240  
cctgcccgtc accagatct gagatcacgc gttctaggat ccccgatga gctaagctag 6300  
ctatatcatc aatttatgta ttacacataa tatcgactc agtcttcat ctacggcaat 6360  
gtaccagctg atataatcag ttattgaaat atttctgaat ttaaacttgc atcaataaat 6420  
ttatgtttt gcttgacta taatacctga cttgttattt tatcaataaa tatttaact 6480  
atattcttt caagatggga attaacatct acaaattgcc ttttcttac gaccatgtac 6540  
gtatcgcg 6548

<210> 5

<211> 6539

<212> DNA

<213> Escherichia coli LE392

<220>

<223> Clone: pTS431

<400> 5

aattcaagct tgacgtcagg tggcactttt cggggaaatg tgccggaaac ccctatttgt 60

ttatTTTct aaatacattc aaatatgtat ccgctcatga gacaataacc ctgataaaatg	120
cttcaataat attgaaaaag gaagagtatg agtattcaac atttccgtgt cgcccttatt	180
cccttttg cggcattttg ctttcgtt tttgctcacc cagaaacgct ggtgaaagta	240
aaagatgctg aagatcagtt gggcacgta gtgggttaca tcgaactgga tctcaacagc	300
ggtaagatcc ttgagagtt tcgccccaa gaacgtttc caatgtatg cactttaaa	360
gttctgctat gtggcgcggt attatcccgt attgacgccc ggcaagagca actcggtcgc	420
cgcatacact attctcagaa tgacttggtt gagtactcac cagtcacaga aaagcatctt	480
acggatggca tgacagtaag agaattatgc agtgcgtcca taaccatgag tgataaacact	540
gcggccaaact tacttctgac aacgatcgga ggaccgaagg agctaaccgc tttttgcac	600
aacatggggg atcatgtaac tcgccttgat cgttggaaac cggagctgaa tgaagccata	660
ccaaacgacg agegtgacac cacgatgcct gtagcaatgg caacaacggt gcgcaaacta	720
ttaactggcg aactacttac tctagcttcc cggcaacaat taatagactg gatggaggcg	780
gataaagttg caggaccact tctgcgctcg gcccttccgg ctggctggtt tattgctgat	840
aaatctggag ccggtgagcg tgggtctcgc ggtatcattt cagcactggg gccagatgg	900
aagccctccc gtatcgtagt tatctacacg acggggagtc aggcaactat ggatgaacga	960
aatagacaga tcgctgagat aggtgcctca ctgattaagc attggtaact gtcagaccaa	1020
gtttactcat atatacttta gattgattta aaacttcatt tttatattaa aaggatctag	1080
gtgaagatcc ttttggctc gagtctcatg accaaaatcc cttaacgtga gtttcgttc	1140
cactgagcgt cagacccgt agaaaagatc aaaggatctt cttgagatcc ttttttctg	1200
cgcgtaatct gctgcttgca aacaaaaaaaaa ccaccgctac cagcggtggt ttgtttccg	1260
gatcaagagc taccaactct tttccgaag gtaactggct tcagcagagc gcagatacca	1320
aatactgtcc ttctagtgtta gccgttagtta ggccaccact tcaagaactc tgttagcaccc	1380
cctacatacc tcgctctgct aatcctgtta ccagtggctg ctgccagtgg cgataagtcg	1440
tgtcttaccg ggttggactc aagacgatag ttaccggata aggccgcagcg gtcgggctga	1500
acggggggtt cgtgcacaca gcccagctt gaggcaacga cctacaccga actgagatac	1560
ctacagcgtg agcattgaga aagcgcacg cttccgaag ggagaaaggc ggacaggtat	1620
ccggtaagcg gcagggtcgg aacaggagag cgcacgagg agcttccagg gggaaacgcc	1680
tggtatctt atagtcctgt cgggttcgc cacctctgac ttgaggctcg atttttgtga	1740
tgctcgtag gggggcggag cctatggaaa aacgcccagca acgcggcctt tttacggttc	1800

ctggccttt	gctggcctt	tgctcacatg	ttcttcctg	cgttatcccc	tgattctgtg	1860
gataaccgta	ttacccgcctt	tgagttagct	gataccgctc	gccgcagccg	aacgaccgag	1920
cgcagcgagt	cagttagcgaa	ggaagcggaa	gagcgccaa	tacgcaaacc	gcctctccc	1980
gcgcgttggc	ctgatcagaa	ttcttcccga	tctagtaaca	tagatgacac	cgcgcgcgat	2040
aatttatcct	agtttgcgcg	ctatattttg	ttttctatcg	cgtattaaat	gtataattgc	2100
gggactctaa	tcataaaaaac	ccatctcata	aataacgtca	tgcattacat	gttaattatt	2160
acatgcttaa	cgttaattcaa	cagaatttat	atgataatca	tcgcaagacc	ggcaacagga	2220
ttcaatctta	agaaaacttta	ttgccaaatg	tttgaacgat	ctgcttcgga	tcctctagat	2280
tactgatttt	tgtaaaggcgc	tgataatggt	ccgttggttt	gtaaatcagc	cagtcgcttg	2340
agtaaagaat	ccggctcgaa	tttctgaagc	ctgatgtata	gttaatatcc	gcttcacgcc	2400
atgttcgtcc	gcttttgccc	gggagtttgc	cttccctgtt	tgagaagatg	tctccgcccga	2460
tgctttccc	cggagcgcacg	tctgcaaggt	tccctttga	tgccacccag	ccgagggcgtt	2520
gtgcttctga	tttgtaatg	taattatcg	gtagcttatg	atatgtctga	agataatccg	2580
caacccgctc	aaacgtgttgc	aataaccggt	accatcgca	cggcttgatg	gatctcttgc	2640
tggacaccgg	gatgcttagga	tgggttatcg	tggccggcgt	gcgtgtgtgg	ctttttaggg	2700
cgcggcgcac	ggcgaaaaa	atgtggcagg	tgagtcacgg	tgcaagcgtg	cgcaagtgac	2760
tgcaacaacc	aaggacggtc	atggcggaaag	cacccacgc	gtccaccgtc	tacaggatgt	2820
agcagtagca	cggtaaaga	agtgttgtcc	cgtccattag	gtgcattctc	accgttggcc	2880
agaacaggac	cgttcaacag	ttaggttgag	ttaggactt	ttacgtggtt	aatgtatggc	2940
aaatagtagt	aaattttgc	cccattggc	tggctgagat	agaacatatt	ctggaaagcc	3000
tctagcatat	ctttttgac	agctaaactt	tgcttcttgc	cttctggc	tagcaatgac	3060
gttgcccatg	tcgtggcaaa	catctggtaa	ggtaactgt	ttcggtttgtt	cccttcaacg	3120
gctcaatccc	cacaggccaa	gctatcctt	ccttggcagt	ataggctcct	tgagagatta	3180
tactaccatt	tttaagtgt	tataaagacg	atgctctcta	accagatcga	tcagaaacac	3240
aaagtttag	cagcgtata	tcccacacac	atacacacac	gaagctatgc	ctcctcattt	3300
tccgagagat	tctgacagt	accagaatgt	cagaatgcc	tttcatggc	acaagtcgat	3360
ccacaagctt	cttgggtggag	gtcaaggtgt	gctattatta	ttcgcttct	aggaaattat	3420
tcagaattag	tgcctttat	cataacttct	ctctgagccg	atgtggttt	ggatttcatt	3480
gttgggagct	atgcagttgc	ggatattctg	ctgtggaaga	acaggaactt	atctgcgggg	3540

gtccttgctg gggcaacatt gatatggttc ctgttcgatg tagtagaata caatataatt 3600  
ccgctccctt gccagattgc cattcttgcc atgcttgta tcttcatttg gtcaaattgc 3660  
gcaccactct tgacaggta ttagcttat ttccctgtgga gatggtagaa aactcagctt 3720  
acagaaatgg catttcacgt agtataacgc aagacattag gtactaaaac tcaactaact 3780  
gtttccgaat ttcaaggccc ctccaaggat cccagaaatc atcatctcg aacatgcctt 3840  
cagagaaatg gcattgaccg tccattacaa actaacgtac actgtatctg ttctttacga 3900  
cattgcatgt gaaaggatc tgaagagatt tctcctggta cataataatc tactcccttg 3960  
ctacgttaat aagagatgta aaaacatgca acagttccag tgccaacatt gtccaaggat 4020  
tgtgcaattc tttctggagc gctaaaattg accagattag acgcatcaga atattgaatt 4080  
gcagagttag ccaataatcc tcataatgtt aatgtgctat tgggttcac tactcaatat 4140  
agttctggac taacaatcag attgtttagt atattaagggt ggttggatct ctattggat 4200  
tgtcggcgat tggaaagtct tgcagcttga caagtctact atatattgggt aggtattcca 4260  
gataaatatt aaattttaaat aaaacaatca cacagaagga tctgcggccg ctagcctagg 4320  
cccgccccca caaaaatctg agcttaacag cacagttgct cctctcagag cagaatcggg 4380  
tattcaacac cctcatatca actactacgt tgtgtataac ggtccacatg ccggtatata 4440  
cgatgactgg ggttgtacaa aggccgcaac aaacggcggtt cccggagttg cacacaagaa 4500  
atttgccact attacagagg caagagcagc agctgacgac tacacaacaa gtcagcaaac 4560  
agacaggttg aacttcatcc ccaaaggaga agctcaactc aagcccaaga gctttgctaa 4620  
ggccctaaca agcccaccaa agaaaaagc ccactggctc acgcttagaa ccaaaaggcc 4680  
cagcagtgtt ccagccccaa aagagatctc cttggcccg gagattacaa tggacgattt 4740  
cctctatctt tacgatctag gaaggaagtt cgaagggtgaa ggtgacgaca ctatgttcac 4800  
cactgataat gagaaggta gcctcttcaa tttcagaaag aatgctgacc cacagatgg 4860  
tagagaggcc tacgcagcag gtctcatcaa gacgatctac ccgagtaaca atctccagga 4920  
gatcaaatac cttcccaaga aggttaaaga tgcagtcaaa agattcagga ctaattgcat 4980  
caagaacaca gagaaagaca tatttctcaa gatcagaagt actattccag tatggacgat 5040  
tcaaggctt cttcataaac caaggcaagt aatagagatt ggagtctcta aaaaggttgt 5100  
tcctactgaa tctaaggcca tgcattggagt ctaagattca aatcgaggat ctaacagaac 5160  
tcgcccgtgaa gactggcgaa cagttcatac agagtcttt acgactcaat gacaagaaga 5220  
aaatcttcgt caacatggtg gagcacgaca ctctggtcta ctccaaaaat gtcaaagata 5280

cagtctcaga agaccaaagg gctattgaga ctttcaaca aaggataatt tcggaaacc 5340  
tcctcgatt ccattgccca gctatctgtc acttcatcga aaggacagta gaaaaggaag 5400  
gtggctcta caaatgccat cattgcgata aaggaaaggc tatcattcaa gatgcctctg 5460  
ccgacagtgg tcccaaagat ggaccccac ccacgaggag catcgtggaa aaagaagacg 5520  
ttccaaccac gtcttcaaag caagtggatt gatgtgacat ctccactgac gtaagggatg 5580  
acgcacaatc ccactatcct tcgcaagacc cttcctctat ataaggaagt tcatttcatt 5640  
tggagaggac acgctgaaat caccagtctc tctctataaa tctatctctc tctctataac 5700  
catggaccca gaacgacgccc cgccgacat ccggcgtgcc accgaggcgg acatgccggc 5760  
ggtctgcacc atcgtcaacc actacatcga gacaagcacf gtcaacttcc gtaccgagcc 5820  
gcaggaaccg caggagtggc cggacgacct cgtccgtctg cgggaggcgt atccctggct 5880  
cgtcgcccgg aggtcgccgg catgcctac gcgggcccct ggaaggcacf 5940  
caacgcctac gactggacgg ccgagtcgac cgtgtacgtc tccccccgccc accagcggac 6000  
gggactggc tccacgctct acacccaccc gctgaagtcc ctggaggcac agggcttcaa 6060  
gagcgtggtc gctgtcatcg ggctgccaa cgacccgagc gtgcgcattgc acgaggcgt 6120  
cgatatgcc ccccgccggca tgctgcgggc ggccggcttc aagcacggga actggcatga 6180  
cgtgggtttc tggcagctgg acttcagecct gccggtagcc ccccggtccgg tcctgcccgt 6240  
caccgagatc tgagatcactc cgttcttagga tcccccgatg agctaagcta gctatatcat 6300  
caatttatgt attacacata atatcgact cagtcttca tctacggcaa tgtaccagct 6360  
gatataatca gttattgaaa tatttctgaa tttaaacttg catcaataaa ttatgtttt 6420  
tgcttgact ataatacctg acttgttatt ttatcaataa atattnaac tatatttctt 6480  
tcaagatggg aattnaacatc tacaaattgc ctttcttat cgaccatgta cgtatcgcg 6539

<210> 6

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer 1

<400> 6  
cgttcggctc gatggtaccg gttatcaaca cgtttga 37

<210> 7  
<211> 38  
<212> DNA  
<213> Artificial Sequence  
<220>  
<223> Primer 2

<400> 7  
cctctagatt atctgatttt tgtaaaggta tgataatg 38